Cite
HARVARD Citation
Hofman, M. et al. (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 397 (10276), pp. 797-804. [Online].